Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 3/20 | 0.74 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.74 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | JAK1 | P23458 | 1/20 | 0.66 |
| ▸ | TYK2 | P29597 | 1/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.66 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 5/20 | 0.58 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 4/20 | 0.56 |
| ▸ | ITK | Q08881 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14658264 | 1.00 | MAPK8 (0.74) | MAPK8MAPK9JAK2JAK1TYK2 | |
| SCHEMBL30879227 | 0.91 | RAB9A (0.62) | MAPK8MAPK9JAK2JAK1TYK2 | |
| SCHEMBL29761515 | 0.88 | MAPK8 (0.71) | MAPK8MAPK9MAP4K1SYKEGFR | |
| SCHEMBL14658247 | 0.88 | MAPK8 (0.71) | MAPK8MAPK9MAP4K1SYKEGFR | |
| SCHEMBL14657944 | 0.88 | MAPK8 (0.61) | MAPK8MAPK9JAK2JAK1TYK2 | |
| SCHEMBL14658234 | 0.87 | MAPK8 (0.73) | MAPK8MAPK9JAK2JAK1TYK2 | |
| SCHEMBL14657519 | 0.86 | MAPK8 (0.73) | MAPK8MAPK9JAK2JAK1TYK2 | |
| SCHEMBL14657966 | 0.85 | MAPK8 (1.00) | MAPK8MAPK9MAP4K1SYKZAP70 | |
| SCHEMBL30879367 | 0.85 | SIRT5 (0.64) | MAPK8MAPK9MAP4K1RAB9ASYK | |
| SCHEMBL14658078 | 0.85 | SYK (0.67) | MAPK8MAPK9JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | MAPK8 45/4885MAPK9 87/4885JAK2 76/4885 |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | MAPK8 45/4885MAPK9 87/4885JAK2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.